Clinical Trial Update: A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR [Phase 2]

View source ↗

Summary

Phase II trial of gefitinib (Iressa) for chemo-refractory germ cell tumors expressing EGFR has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Germ Cell Tumor

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: Indiana University School of Medicine | Conditions: Refractory Germ Cell Tumors Expressing EGRF | Phase 2 | Status: TERMINATED